Sharon Benzeno compensation by year
Adaptive Biotechnologies Summary Compensation Table · the one fiscal year held| Component | FY2022 |
|---|---|
| Salary | $456,250 |
| Bonus | $0 |
| Stock awards | $999,996 |
| Option awards | $1,566,497 |
| Non-equity incentive | $210,781 |
| Pension and deferred compensation | $0 |
| All other | $4,260 |
| Total | $3,237,784 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Adaptive Biotechnologies Corp DEF 14A filed April 28, 2023, accession 0001193125-23-126845, and prior-year filings. Open the filing on EDGAR.
How this page was built: the Adaptive Biotechnologies Corp filed document, accession 0001193125-23-126845. Every figure is read from that document and cited to the page and table it appears in. Filed April 28, 2023.
Equity holdings
unvested awards at FY2024 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| RSU | 132,979 | $797,209 | — |
| RSU | 99,735 | $597,911 | — |
| RSU | 41,186 | $246,910 | — |
| RSU | 5,724 | $34,315 | — |
| Option | 112,247 | — | $8.46 |
| Option | 3,578 | — | $43.68 |
| Option | 64,354 | — | $12.14 |
| Option | 199,549 | — | $3.99 |
Per the Outstanding Equity Awards at Fiscal Year-End table in Adaptive Biotechnologies Corp's FY2024 proxy; value at the fiscal year-end close, as the company printed it.
Insider transactions since the last proxy
47 Form 4 lines since the FY2022 proxy (filed April 28, 2023)current to 2026-11-21 · updated nightly
| Date | Transaction | Plan | Shares | Price | Held after |
|---|---|---|---|---|---|
| 2026-06-29 | Sale | 10b5-1 | 154,768 | $21.14 | 221,278 |
| 2026-06-29 | Exercise or conversion derivative | 10b5-1 | 24,944 | $0.00 | 37,416 |
| 2026-06-29 | Exercise or conversion | 10b5-1 | 1,837 | $12.14 | 274,588 |
| 2026-06-29 | Exercise or conversion derivative | 10b5-1 | 24,944 | $0.00 | 87,303 |
| 2026-06-29 | Exercise or conversion | 10b5-1 | 51,570 | $8.12 | 376,046 |
| 2026-06-29 | Exercise or conversion | 10b5-1 | 24,944 | $8.46 | 299,532 |
| 2026-06-29 | Exercise or conversion | 10b5-1 | 24,944 | $3.99 | 324,476 |
| 2026-06-29 | Exercise or conversion derivative | 10b5-1 | 51,570 | $0.00 | 113,457 |
The 8 most recent of 47 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →
Adaptive Biotechnologies’s named executive officers, FY2022
as the company reported each| Named executive officer | Role | FY2022 total |
|---|---|---|
| Chad Robins | Chief Executive Officer | $8,853,328 |
| Harlan Robins | Chief Scientific Officer | $8,459,087 |
| Julie Rubinstein | President and Chief Operating Officer | $6,535,078 |
| Tycho Peterson | Chief Financial Officer | $5,938,257 |
| Sharon Benzeno · this page | Chief Commercial Officer, Immune Medicine | $3,237,784 |
| Kyle Piskel | Interim Chief Financial Officer | $1,659,147 |
| Chad Cohen | Former Chief Financial Officer | $72,221 |
The full Adaptive Biotechnologies compensation record
free company briefThis page is one person within Adaptive Biotechnologies's record. The company brief lists every named executive, each linking to their own page.
Peer companies
named in the Adaptive Biotechnologies proxy · each links to its own free briefCompensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Adaptive Biotechnologies's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.